"Site Support Office"

During the past decade, Clinical Neuroscience Solutions, Inc. conducted 116 clinical trials. In the 10-year time frame, 116 clinical trials started and 100 clinical trials were completed, i.e. on average, 86.2% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 68 clinical trials were completed. i.e. 144.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinical Neuroscience Solutions, Inc." #1 sponsor was "Shire" with 27 trials, followed by "Pfizer" with 26 trials sponsored, "Sunovion" with 16 trials sponsored, "Allergan" with 8 trials sponsored and "Eli Lilly and Company" with 8 trials sponsored. Other sponsors include 82 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinical Neuroscience Solutions, Inc." #1 collaborator was "Pfizer" with 4 trials as a collaborator, "Purdue Pharma LP" with 2 trials as a collaborator, "Veristat, Inc." with 2 trials as a collaborator, "CoLucid Pharmaceuticals" with 1 trials as a collaborator and "GlaxoSmithKline" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Clinical Neuroscience Solutions, Inc." are "Major Depressive Disorder" (21 trials), "ADHD" (9 trials), "Attention Deficit Hyperactivity Disorder (ADHD)" (9 trials), "Attention Deficit Hyperactivity Disorder" (8 trials) and "Binge Eating Disorder" (6 trials). Many other conditions were trialed in "Clinical Neuroscience Solutions, Inc." in a lesser frequency.

Most popular intervention types in "Clinical Neuroscience Solutions, Inc." are "Drug" (156 trials), "Biological" (16 trials), "Other" (16 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (89 trials), "Dasotraline" (6 trials), "placebo" (5 trials), "Atogepant" (4 trials) and "BNT162b2" (4 trials). Other intervention names were less common.

The vast majority of trials in "Clinical Neuroscience Solutions, Inc." are 167 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Clinical Neuroscience Solutions, Inc.". undefined are not yet recruiting, 9 are recruiting, 11 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 136 completed trials in Clinical Neuroscience Solutions, Inc., 1 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Clinical Neuroscience Solutions, Inc., 3 "Phase 1" clinical trials were conducted, 55 "Phase 2" clinical trials and 109 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 1 trials that are defined as “Not Applicable".